<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01387373</url>
  </required_header>
  <id_info>
    <org_study_id>MA 0919</org_study_id>
    <nct_id>NCT01387373</nct_id>
  </id_info>
  <brief_title>Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer</brief_title>
  <official_title>Intra-hepatic Chemotherapy With Oxaliplatin Every Second Week in Combination With Systemic Capecitabine in Patient With Non-resectable Liver Metastases From Breast Cancer. A Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dorte Nielsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second
      week in combination with systemic capecitabine and in patients with a HER2-positive tumour in
      combination with trastuzumab (Herceptin®) in patient with non-resectable liver metastases
      from breast cancer.

      Only patients without extrahepatic disease are included.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>6 months after inclusion of last patient</time_frame>
    <description>Number of patients with complete or partial response in the liver (RECIST version 1.1)Only patients with measurable disease are included in the protocol. Response rate number of patients with CR + PR divided with total number</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression a) Intrahepatic progression b) Extrahepatic progression</measure>
    <time_frame>6 months after inclusion of last patient</time_frame>
    <description>Time from treatment start to progression of disease or death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients suitable for local therapy (radiofrequency)</measure>
    <time_frame>6 months after inclusion of last patient</time_frame>
    <description>Total number of patients receiving RF treatment or surgical treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>6 months after inclusion of last patient</time_frame>
    <description>All patients in intent-to-treat population , calculated from start of treatment to death of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>28 days after last patient last dose</time_frame>
    <description>All patients who received at least one dose of study drug are evaluable for toxicity. CTC version 3.0 will be used.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin, capecitabine, trastuzumab</intervention_name>
    <description>Oxaliplatin intrahepatic capecitabine + trastuzumab systemic</description>
    <arm_group_label>chemotherapy</arm_group_label>
    <other_name>HAI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Age &gt; 18 years

          -  Performance status 0-1; expected survival ≥ 3 months

          -  Patient with histologically or cytologically confirmed locally advanced or metastatic
             adenocarcinoma of the breast

          -  Liver metastases not suitable for local treatment

          -  Extrahepatic disease should be excluded by PET-CT-scan.

          -  No progression on treatment with capecitabine.

          -  Prior treatment with taxane (adjuvant or for metastatic disease)

          -  Metastases &lt; 70 % of the liver

          -  Neutrophile granulocytes &gt; 1.5 x 109/l og thrombocytes &gt; 100 x 109/l

          -  Bilirubin &lt; 2.0 x UNL (upper normal limit).

          -  Creatinine-clearance &gt; 30 ml/min.

          -  INR &lt; 1.6.

          -  If the patient is HER2-positive:Baseline LVEF ≥ 50 %.

        Exclusion Criteria:-

          -  History of chemotherapy within the 4-week period prior to the start of trial
             medication

          -  Other current or prior malignant disease except adequately treated and cured carcinoma
             in situ of the cervix or squamous cell carcinoma of the skin.

          -  Previous treatment with oxaliplatin

          -  Cytotoxic or experimental treatment within a 14 days period before start of trial
             medication

          -  The patient is not allowed to participate in other clinical trials.

          -  Any clinical symptoms suggesting peripheral neuropathy &lt; or equal to grade 2 or CNS
             metastases (In case of clinical suspicion on CNS metastases a MR or CT scan should be
             performed within 4 weeks before inclusion

          -  Other severe medical conditions e.g. severe cardial disease or AMI &lt; 1 year

          -  Presence of diseases which prevent oral therapy. • Patients with uncontrolled
             infection

          -  Pregnant or lactating women

          -  Women capable of childbearing not using a sufficient non—hormonal method of birth
             control

          -  Patients not able to understand the treatment or to collaborate.

          -  Prior serious or unsuspected reaction after treatment with fluoropyrimidine

          -  Known prior hypersensitivity reactions to the agents.

        If the patient is HER2-positive:

        • Dyspnoea in due to complication related to malignant disease e.g.lung metastases with
        lymphangitis or other conditions with need of supportive oxygen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorte Nielsen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorte Nielsen, Professor</last_name>
    <phone>+4544884000</phone>
    <phone_ext>82344</phone_ext>
    <email>dornie01@heh.regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Birgitte Krogh Jensen, Study nurse</last_name>
    <phone>+4544884000</phone>
    <phone_ext>89562</phone_ext>
    <email>bikrje01@heh.regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorte Nielsen, Professor</last_name>
      <phone>+4544884000</phone>
      <phone_ext>82344</phone_ext>
      <email>dornie01@heh.regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Birgitte Krogh Jensen, Study nurse</last_name>
      <phone>+454488000</phone>
      <phone_ext>89562</phone_ext>
      <email>bikrje01@heh.regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Dorte Nielsen, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorte Nielsen</last_name>
      <phone>+4544884000</phone>
      <phone_ext>82344</phone_ext>
    </contact>
    <investigator>
      <last_name>Dorte Nielsen, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2011</study_first_submitted>
  <study_first_submitted_qc>July 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2011</study_first_posted>
  <last_update_submitted>March 20, 2014</last_update_submitted>
  <last_update_submitted_qc>March 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Dorte Nielsen</investigator_full_name>
    <investigator_title>Responsible Party was entered in the old format as Dorte Nielsen, professor DMSci, Department of Oncology, Herlev Hospital.</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>liver metastases</keyword>
  <keyword>intrahepatic</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

